Lívia Alves Filgueiras

Dr. Lívia Alves Filgueiras

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in BioNanoScience
Verified
Journal Article
Closed access
PDF file
DLDiego Botelho Campelo Leite
Diego Botelho Campelo Leite
EMEdmilson Miranda de Moura
Edmilson Miranda de Moura
Edvani MunizEdvani Muniz
Edvani Muniz
Edson Silva FilhoEdson Silva Filho
Edson Silva Filho
AMAnderson Mendes
Anderson Mendes
CMCarla Veron̂ica Rodarte De Moura
Carla Veron̂ica Rodarte De Moura

Verified
Journal Article
Open access
PDF file
TVThiago Ferreira Cândido Lima Verde
Thiago Ferreira Cândido Lima Verde
MVMatheus Ribeiro Viana
Matheus Ribeiro Viana
AFAndré Sales Aguiar Furtado
André Sales Aguiar Furtado
GBGuilherme Castro Brito
Guilherme Castro Brito
MCManuel Henrique De Sousa Cunha
Manuel Henrique De Sousa Cunha
Anderson de Oliveira LoboAnderson de Oliveira Lobo
Anderson de Oliveira Lobo
This study addresses the challenges of osteochondral tissue engineering by developing a hybrid scaffold with intercalated layers of poly(ε-caprolactone) (PCL) in combination with different concentrations of nanosized synthetic smectic clay (Lap) and a hydrogel of chitosan, collagen and demineralized bone powder (DBP). The scaffold design specifically targets the critical junction between subchondral bone and calcified cartilage and utilizes the mechanical strength of PCL/Lap nanocomposites and the bioactivity of the chitosan/collagen/DBP hydrogel to support tissue regeneration. The PCL/Lap nanocomposite, characterized by increased hydrophilicity, improved swelling behavior, and enhanced stiffness, provides a robust scaffold, while the hydrogel layers improve bioactivity and fluid retention. Three-dimensional printing technology was used to fabricate multi-layer scaffold, ensuring interfacial cohesion between the layers. Rheological, morphological, chemical, and mechanical characterizations confirmed the successful integration of the materials and the mechanical suitability for the subchondral environment. Biocompatibility assays demonstrated the non-hemolytic nature of the scaffolds and a favorable trend in cell viability with increasing Lap content. This study presents a novel scaffold design that effectively combines mechanical stability and biological functionality. It fulfills the complex requirements of osteochondral repair and offers a promising platform for future tissue engineering strategies.

22 July 2026 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
MCMATEUS C P H COSTA
MATEUS C P H COSTA
LFLívia Alves Filgueiras
Lívia Alves Filgueiras
AMAnderson Mendes
Anderson Mendes
Background: Geraniol is an acyclic monoterpene widely distributed in the essential oils of aromatic species such as Cymbopogon citratus, Pelargonium graveolens, and Rosa damascena, It is known for its antioxidant, anti-inflammatory, neuroprotective, and antitumor activities. Methods: This study aimed to investigate, through network pharmacology and computational ADMET modeling, the molecular mechanisms and pharmacological potential of geraniol, integrating drug-likeness parameters, toxicity prediction, and multitarget interactions. Results: A total of 25 core targets were identified, mainly involved in inflammation, oxidative stress, apoptosis, and transcriptional regulation. Geraniol exhibited a favorable drug-likeness profile, high predicted intestinal absorption, and low systemic toxicity, supporting its pharmaceutical applicability. Mechanistically, it modulates the Nrf2/HO-1 ↔ NF-κB axis, reducing reactive oxygen species, pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and apoptotic markers (caspases, Bax), while enhancing antioxidant enzymes (SOD, CAT, GPx) and antiapoptotic proteins (Bcl-2). Conclusions: These findings confirm its multitarget and pleiotropic nature, highlighting its potential as a therapeutic candidate for inflammatory, metabolic, and neurodegenerative disorders. Furthermore, this study provides a robust mechanistic rationale for future in vitro and in vivo validation, as well as for the design of nanostructured formulations to improve geraniol’s bioavailability and therapeutic safety.